Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder
- PMID: 34420071
- DOI: 10.1007/s00277-021-04645-2
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder
References
-
- Jiang H, Gao H, Wang Q, Wang M, Wu B (2020) Molecular mechanisms and clinical application of Iguratimod: a review. Biomed Pharmacother 122:109704. https://doi.org/10.1016/j.biopha.2019.109704 - DOI - PubMed
-
- Tokuhira M, Tamaru J, Kizaki M (2019) Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 59:72–92. https://doi.org/10.3960/jslrt.19007 - DOI - PubMed - PMC
-
- Maegawa S, Kuroda J, Kobayashi T, Fuchida S, Kawata E, Kamitsuji Y et al (2015) Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma. Leuk Lymphoma 56:785–788. https://doi.org/10.3109/10428194.2014.928936 - DOI - PubMed
-
- Kobe H, Ito A, Hayata H, Nishimura K, Ueda Y, Ishida T (2021) Mycophenolate mofetil-induced diffuse large B-cell lymphoma in which a solitary lung nodule remitted spontaneously. Intern Med 60:131–136. https://doi.org/10.2169/internalmedicine.5027-20 - DOI - PubMed
-
- Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68:1–26. https://doi.org/10.1002/art.39480 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
